Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday.
about
Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw.Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.Longitudinal change in clinical fracture incidence after initiation of bisphosphonatesAdherence to osteoporosis treatments: room for improvementDevelopment of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosisFemoral insufficiency fractures associated with prolonged bisphosphonate therapy.Bisphosphonate drug holidays: Can we recommend currently?Drug Holidays From ADHD Medication: International Experience Over the Past Four Decades.Adherence and profile of non-persistence in patients treated for osteoporosis--a large-scale, long-term retrospective study in The Netherlands.Subgroup variations in bone mineral density response to zoledronic acid after hip fracture.Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis.Measuring and improving adherence to osteoporosis pharmacotherapy.Long-term safety concerns of antiresorptive therapy.Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort studyRisedronate's Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis.Methods to examine the impact of compliance to osteoporosis pharmacotherapy on fracture risk: systematic review and recommendationsBisphosphonate prescribing, persistence and cumulative exposure in Ontario, CanadaBisphosphonate Use and Risk of Implant Revision after Total Hip/Knee Arthroplasty: A Meta-Analysis of Observational StudiesThe Prevention of Medication-related Osteonecrosis of the Jaw.Bisphosphonate Treatment in Osteoporosis: Optimal Duration of Therapy and the Incorporation of a Drug Holiday.Physicians' perspectives on the treatment of osteoporosis patients with bisphosphonates.Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis.The impact of persistence with bisphosphonates on health resource utilization and fracture risk in the UK: a study of patient records from the UK Clinical Practice Research Datalink.Discontinuation and reinitiation patterns of osteoporosis treatment among commercially insured postmenopausal women.Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis.Progress in osteoporosis and fracture prevention: focus on postmenopausal women.Bisphosphonates in the treatment of metabolic bone diseases.Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws.Hip fracture prevention with a multifactorial educational program in elderly community-dwelling Finnish women.Identifying atypical femoral fractures--a retrospective review.Fractures and mortality in relation to different osteoporosis treatments.The effects of discontinuing long term alendronate therapy in a clinical practice setting.Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study.Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice.Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk.Residual effect after oral bisphosphonate treatment and healthy adherer effects--the Swedish Adherence Register Analysis (SARA).Role of Teriparatide in Medication-Related Osteonecrosis of the Jaws (MRONJ).Les bisphosphonates dans le traitement de l’ostéoporose: Bienfaits attendus, torts potentiels et congés thérapeutiques.
P2860
Q30239854-33313FDB-ED9B-45A9-A180-3703302F1323Q33715141-C1F8724A-0643-43CC-8CB0-049BA3BE22A0Q33819111-9CE4388F-9EC2-47DE-8B53-6A437D455F6DQ34033742-F4E23E66-CDD5-42A3-9A19-56F8B79016F5Q34042003-23F7F9F6-F6D2-4A38-AD23-5E9E78A7394FQ34283690-DFA3271F-7D20-41E6-9BEE-83D55866B3E6Q34329746-7F882FF5-A144-4E52-9B8F-67F87B08F654Q34440332-CACAE437-0F44-45C2-BE40-99EB1142C031Q34774658-C126FA77-1D89-48BA-BD0B-0C417AA651D6Q35017673-56B09C41-7A1B-47E9-9865-F9137531AE96Q35050241-825413BF-49E8-49C0-AC09-9453F4218889Q35177690-EA4A193D-8A52-44AC-824D-0456CA06AA74Q35570961-99F90E6A-68CB-4512-BE93-D1E4B38BEFBDQ35596890-2D06821A-5886-4C60-AA5A-7B98220035DCQ35678676-68137E85-104A-4A15-A28B-7D9F0123DDFBQ35693057-569AF466-C42F-4791-AD16-5396637BA2EAQ35751437-36CD161C-8082-4454-8C8D-188A40A8E417Q36132924-B131F5FC-360F-4F31-BC36-68A4BA46FB4FQ36292333-68A32BB9-6555-4FE9-BFFA-BA263FFF3BCEQ36523054-0FF258D6-99A7-47C0-A02B-6FC8A56DB8C6Q36598506-0A581A3F-9E58-4E77-9130-452AADCEFD76Q37274269-B8196CDD-2976-45B6-A7B8-F09432AB0504Q37296051-282E7E6B-DD2A-4359-AC9F-1C24F9D2C256Q37302546-4918F9B6-4402-41C5-B78A-5BEBFD3B7F9CQ37407681-F53F853E-81BA-4F56-8392-38B5C695C291Q37453973-BB8D845E-D3A9-4B48-8A86-0F2AB3BF2504Q37756594-35984C91-D2A7-414B-9D75-EC4B18BDAA46Q37862933-97441834-271E-448A-A72D-7FF1CA770778Q37973240-F6ECA2D9-ED93-452B-9A68-1ADC55781E2FQ38104924-4AC0FD13-9CEB-4FDE-B025-0E4001432DC7Q38248253-AC7AFB36-8F83-4513-9AD7-884B203A406DQ43577539-E978AAA9-0074-4C49-81F5-C30687CCD908Q44114149-2A904331-96EC-4CE1-835E-693EF4A33227Q44381104-4468C69B-494B-46C5-A5CD-7C80D1647027Q46244082-3776D04E-2A12-4254-95F8-0A050582A852Q47279165-67BB77B4-2A8F-484F-970E-C84EA2C2F1CAQ50629864-DDB9514D-8A0D-4494-AF96-19CDEA959BCEQ55255208-91B14626-105A-4C2C-B3AE-E04ABB93909DQ55452474-53154E5E-BABD-4AC0-8488-ED4145275AEB
P2860
Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Risk of hip fracture after bis ...... plications for a drug holiday.
@en
type
label
Risk of hip fracture after bis ...... plications for a drug holiday.
@en
prefLabel
Risk of hip fracture after bis ...... plications for a drug holiday.
@en
P2093
P2860
P1476
Risk of hip fracture after bis ...... plications for a drug holiday.
@en
P2093
P2860
P2888
P304
P356
10.1007/S00198-008-0604-4
P407
P577
2008-05-16T00:00:00Z